36 completed, 16 recruiting, 8 active not recruiting, 6 unknown. 76 Phase 1, 27 Phase 2.
Follow Hodgkin Lymphoma: new trials by email Literature Review of Hodgkin Lymphoma trials Research Report on Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| CD45BE-HSPC + CART-45 Cells CART-45 cells, CD45BE-HSPC - B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation | Phase 1 | Recruiting | University of Pennsylvania | 42 | 2026-08-05 | 2026-08-10 |
| PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma PD-1+JAK1i, PD-1 - Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-06-30 | 2026-06-11 |
| Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide - Lymphoid, Hodgkin Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-05-28 | 2026-09-08 |
| A Phase I Study of JLM019 Injection JLM019 Injection - Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 115 | 2026-01-13 | 2026-06-03 |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. Omeprazole, Dextromethorphan - Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Murdoch Childrens Research Institute | 10 | 2025-07-22 | 2026-08-27 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| PTCy and ATG for MSD and MUD Transplants ATG 5.0, Cyclophosphamide injection, ATG 4.0 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Instituto Nacional de Cancer, Brazil | 50 | 2024-06-14 | 2025-02-25 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies CTX-8371 - Non Small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1 | Recruiting | Compass Therapeutics | 85 | 2024-03-19 | 2026-07-28 |
| AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. AZD3470, Pembrolizumab - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 161 | 2024-01-23 | 2026-10-13 |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma MT-601 - Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory | Phase 1 | Recruiting | Marker Therapeutics, Inc. | 79 | 2023-01-02 | 2026-09-15 |
| First in Human, Dose Escalation, Dose Expansion Study of AUR105 AUR105 - Solid Tumor, Adult, Non-hodgkin Lymphoma | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 17 | 2022-11-30 | 2026-04-17 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
Showing 20 of 76. Sign in to see all of them.
Hodgkin Disease (76) · Lymphoma, Non-Hodgkin (35) · Multiple Myeloma (17) · Myelodysplastic Syndromes (17) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Leukemia, Myeloid, Acute (12) · Lymphoma (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Lymphoma, Large-Cell, Anaplastic (10) · Lymphoma, Large B-Cell, Diffuse (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Lymphoma, Follicular (8) · Lymphoma, T-Cell, Peripheral (8) · Recurrence (8) · Hematologic Neoplasms (7)
Hemic and Lymphatic Diseases (76) · Immune System Diseases (76) · Immunoproliferative Disorders (76) · Lymphatic Diseases (76) · Neoplasms (76) · Neoplasms by Histologic Type (76) · Lymphoproliferative Disorders (74) · Lymphoma (65) · Hematologic Diseases (29) · Pathologic Processes (27) · Pathological Conditions, Signs and Symptoms (27) · Disease Attributes (26) · Leukemia (23) · Blood Protein Disorders (19) · Cardiovascular Diseases (19)
Cyclophosphamide (10) · Nivolumab (8) · fludarabine (8) · fludarabine phosphate (8) · Brentuximab Vedotin (7) · Azacitidine (4) · Bendamustine Hydrochloride (4) · Dexamethasone (4) · Whole-Body Irradiation (4) · pembrolizumab (4) · Etoposide (3) · Lenalidomide (3) · Mycophenolic Acid (3) · Sirolimus (3) · Antilymphocyte Serum (2)
Baylor College of Medicine (4) · M.D. Anderson Cancer Center (4) · Affimed GmbH (2) · Bristol-Myers Squibb (2) · City of Hope Medical Center (2) · Columbia University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Millennium Pharmaceuticals, Inc. (2) · New York Medical College (2) · University of Cologne (2) · ADC Therapeutics S.A. (1) · Acerta Pharma BV (1) · Alla Keyzner (1) · Angiocrine Bioscience (1)
United States (58) · China (6) · Spain (6) · Australia (4) · France (4) · Germany (4) · Belgium (3) · Canada (3) · Italy (3) · United Kingdom (3) · Brazil (2) · Denmark (2) · Japan (2) · Czechia (1) · Greece (1)
Alison Moskowitz, MD (2) · Hayder Saeed, MD (2) · Helen Heslop, MD (2) · Premal Lulla, MD (2) · Adam Lamble, MD (1) · Alla Keyzner, MD (1) · Anas Younes, MD (1) · Anas Younes, Professor (1) · Andreas Engert, Prof. (1) · Andreas Engert, Professor (1) · Anton Hagenbeek, PhD MD (1) · Benjamin Tomlinson, MD (1)
PMID 21841163, PMID 23459515, PMID 25482239, PMID 25887777, PMID 27269947, PMID 27354476, PMID 28490569, PMID 29141948, PMID 29229594, PMID 29276022, PMID 30937889, PMID 31355467, PMID 31395089, PMID 31401903, PMID 31471376, PMID 31609651, PMID 32273476, PMID 32556281, PMID 32730586, PMID 32871584, PMID 33062947, PMID 33171487, PMID 33507803, PMID 33598942, PMID 33635333, PMID 33666654, PMID 33827139, PMID 34048682, PMID 34413145, PMID 34495306, PMID 35244520, PMID 36241696, PMID 36333463, PMID 36333464, PMID 36398795, PMID 36594185, PMID 37722357, PMID 38517235, PMID 39661923, PMID 39908567, PMID 40042547, PMID 40259519, PMID 41144785, PMID 42545812
2015 (1), 2018 (1), 2023 (1), P30CA033572 (1), P30CA138292 (1), P50CA126752 (1), R01HL180913 (1)